drugset
drugset / Trial / NCT00052312

Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer

NCT00052312 ↗

Phase 2 Completed 141 enrolled European Organisation for Research and Treatment of Cancer - EORTC
RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether doxorubicin and cisplatin are more effective with or without paclitaxel in treating endometrial cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of combining doxorubicin and cisplatin with or without paclitaxel in treating patients who have locally advanced, metastatic, and/or relapsed endometrial cancer.

Timeline

Start
2002-09
Primary completion
2006-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Doxorubicin Other / unclassified — Intravenous

Indications

endometrial cancer